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 SOX10 is a transcription factor that plays an important role in the formation, specication and di#erentiation of neural 
crest cells. Recent studies indicate that this protein is expressed in tumors of the nervous system, salivary glands, breast, 
soft tissues and melanoma cells. Due to its higher sensitivity and specicity in comparison to other available markers, 
SOX10 protein is mainly used in the diagnosis of malignant peripheral nerve sheet tumor and primary and metastatic 
melanoma including desmoplastic type. SOX10 has a more readable immunohistochemical staining, which also facilitates 
histopathological interpretation. Several monoclonal and polyclonal antibodies for diagnostics are currently available. 
Unication of anti-SOX10 antibodies to increase specicity, eliminate variability and strength of immunohistochemical 
reactions will support its diagnostic usefulness.
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Proteins from the SOX family
The sex-determining region Y (SRY) gene responsible for the 
male sex that was found on the Y chromosome gave rise to 
the class of genes called SOX. The name of SOX [SRY-related 
high-mobility group (HMG) box] indicates that the class of 
genes has a common construction of the high mobility group 
(HMG) domain. The HMG domains in all SOX proteins have 
a similar structure and all are thought to be capable of binding 
to the same DNA sequence – AACAA (A / T) G. The family of 
SOX genes is indispensable in many processes including: the 
development of the nervous and immune systems, the forma-
tion of pigment cells, sex determination, skeletal genesis and 
in the development of the eyes [1]. SOX proteins, due to their 
ability to bind DNA through the HMG domain, are included in 
DNA-binding proteins. In mammals, the family of SOX proteins 
consists of about 20 transcription factors. Nine groups of SOX 
proteins have been isolated according to transcription factors 
content: A, B1, B2, C, D, E, F, G and H. It has been proven that 
each group includes proteins showing > 80% of similarity in 
the HMG domain construction. SOX10 together with SOX9 
and SOX8 form a group of SOXE transcription factors [1, 2].
SOX10 structure and functions
SOX10 is a transcription factor encoded by the SOX10 gene 
located on the long arm of chromosome 22 at position 22q13.1 
and encodes 446 amino acids. SOX10 plays a key role in the 
development of testes, oligodendrocytes, the central nervous 
system and chondrocytes [3]. The regulation of SOX10 func-
tions consists in binding this protein to promoters or enhancers 
of transcription in target genes, alone or in combination with 
other transcription factors [4, 5]. SOX10 is responsible for a 
number of important functions in the body. Its crucial role is 
participation in maintaining the pluripotency of progenitor 
cells via the specication and di#erentiation of cell lines and 
the formation of neural crest cells. The products of these cells 
include: neural and glial cells in the peripheral nervous system, 
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skin melanocytes, thyroid gland, adrenal medulla and visceral 
sacroiliac cartilage [6–8]. Additionally, SOX10 is essential in the 
process of central and peripheral nervous system myelination. 
In Schwann cells, SOX10 regulates the transcription of myelin 
proteins, such as zero proteins, peripheral myelin 22 and con-
nexin 32 [9, 10]. Another function of SOX10 is the regulation of 
lipophilin and basic myelin protein transcription in oligoden-
drocytes. According to recent studies, SOX10 is a regulator of 
c-RET – a protein tyrosine kinase receptor that plays a central 
role in the development of the intestinal nervous system. 
SOX10 is also indispensable in the process of regulating the 
transcription of genes necessary for the synthesis of melanin, 
such as: DOPA chromium tautomerases, tyrosinase and tyrosi-
nase-related protein [1, 11–15]. Figure 1 presents the location 
and major functions of the SOX10 gene. 
The germline SOX10 mutations were identied in the Wa-
ardenburg-Shah syndrome type II and type IV. These mutations 
include mainly reading frame shift, nonsense type and one 
splicing site [6, 16]. The Waardenburg-Shah syndrome is cha-
racterized by the presence of bilateral deep hearing loss and 
pigment abnormalities. The irregularities associated with the 
depigmentation include: white hair, blue iris with gray spots 
and skin discoloration [6, 16, 17]. Type IV of Waardenburg-Shah 
syndrome is the rarest of four main types. It occurs with a fre-
quency < 1 per 1 000 000 and so far only about 100 cases were 
reported [18]. SOX10 mutations were also detected in a more 
severe syndrome characterized by the association of the featu-
res of Waardenburg-Shah syndrome with peripheral demyeli-
nating neuropathy-central dysmyelinating leukodystrophy and 
Hirschsprung disease (PCWH), which is a congenital functional 
disorder of the gastrointestinal motility due to the lack of inte-
stinal nerve ganglia [19, 20]. In the autosomal dominant form 
of Kalmann’s syndrome, the SOX10 loss of function mutations 
were found in about 38% cases. The disease is characterized 
by congenital hypogonadotropic hypogonadism and anosmia 
or hyposmia [6]. The Yemenite deaf-blind hypopigmentation 
syndrome characterized by hypopigmentation, small cornea, 
coloboma and the occurrence of severe hearing loss is also 
caused by mutations in the SOX10 gene [21]. 
It is important that SOX10 together with the NOTCH1 pro-
tein in!uence proliferation and resistance to radiation in many 
cancer stem cells i.e. prostate cancer [22]. Selective expression 
of SOX10 in normal tissues, i.e. peripheral nerves, glandular cells 
in salivary or sweat glands in comparison with highly specic 
immunohistochemical staining in melanoma, schwannoma, 
malignant peripheral nerve sheath tumor, myoepithelial, and 
some salivary gland tumors make this protein useful in the 
routine histopathological diagnostics [23, 24]. Currently, a large 
selection of anti-SOX10 antibodies is available, including poly 
– and monoclonal clones. The authors present the importance 
of SOX10 in the histopathological diagnostics and the review 
of antibodies used in the immunohistochemical assessment.
SOX10 as a melanocytic marker
Melanoma is a deadly skin disease known for its aggressive 
course and high risk of metastasis. This disease may show 
a wide range of morphological features, which gives rise to 
di"culties in interpretation. Diagnosis of melanoma still re-
mains complicated, because ambiguous melanocytic changes 
may show features that overlap with melanoma and benign 
changes. Therefore, accurate clinical diagnosis in patients is 
highly relevant to further clinical management [25]. 
SOX10 is one of the recently known immunohistoche-
mical markers useful in the diagnosis of tumors arising from 
melanocytes. It directly a#ects the microphthalmia-associated 
transcription factor (MITF), which regulates the transcription 
transctiption responsible for melanin synthesis and survival of 
postnatal melanocytes. SOX10 also in!uences the expression 
of other genes that mediate melanin synthesis [26–28]. In 
several publications SOX10 was shown as a highly sensitive 
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Figure 1. Chromosome location and major functions of the SOX10 gene
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and specic melanocytic marker, which can be used in the 
diagnosis of melanoma [24, 29]. The rst study, in which the 
expression of SOX10 in immunohistochemistry in melanomas 
was studied, was the research work of Gershon et al. The pre-
sence of positive immunohistochemical reactions was noted 
in all analyzed melanoma cells [30]. 
In 2014, Mohamed et al. also conrmed 100% expression 
of SOX10 in melanoma stem cell. High SOX10 expression 
excluded the possibility of using this protein as a prognostic 
marker, but its diagnostic utility was evaluated [31]. SOX10 
protein showed 100% expression in primary cutaneous and 
capsular lymph node nevi, 95–100% in primary and 97–100% 
in metastatic melanoma lesions [24, 32, 33]. Moreover, the pre-
sence of high expression of SOX10 in desmoplastic melanoma 
cells has also been demonstrated [23, 24, 34]. In addition, it was 
proven that the expression of SOX10 was stronger and more 
homogenic than the S100 staining. Karamchandani and et 
al. found positive expression of SOX10 and S100 in 78% and 
57% in desmoplastic melanoma respectively [23]. Ramos-
-Herberth et al. showed a signicant dierence of the staining 
intensity between desmoplastic melanoma cells – high and 
strong expression, and brocytes/spindle histiocytes – weak 
or no expression of SOX10 protein. The results indicated that 
immunohistochemical evaluation of SOX10 can be used to 
dierentiate desmoplastic melanomas from post-traumatic 
scars as well [34].
A large number of reports regarding very high sensitivity of 
the SOX10 protein in melanoma may indicate that it is a good 
marker in the diagnosis of this neoplasm. In contrast to the 
S100 marker, SOX10 is not expressed in dendritic cells. Limited 
positive background eect indicates that SOX10 might be 
even a better diagnostic marker [29]. The expression of SOX10 
protein can also be very helpful in the diagnosis of melanoma 
metastases to sentinel lymph nodes due to its high sensitivity 
and lack of expression in dendritic cells [35]. SOX10 may be 
used in dierential diagnosis of melanoma in situ, as well as 
solar keratosis with melanocytic hyperplasia [36].
Reviewed studies on SOX10 expression were based on 
heterogeneous groups of tissues, sometimes without statistical 
signicance. In addition, the comparative analysis to other 
well-known melanoma markers, including S100, HMB45 or 
Melan A was limited. The lack of a large scale comparative 
research still does not allow for dening recommendation of 
SOX10 as a rst-line marker or at least an equivalent to S100 
in the diagnosis of melanoma.
SOX10 in tumors of the nervous system
Central nervous system (CNS) tumors are a heterogeneous 
group of neoplasms constituting about 3% of all cancers, and 
they are responsible for 7% of all cancer deaths. In the nervous 
system, positive expression of SOX10 is evident in oligoden-
drocytes, sensory and sympathetic ganglia, Schwann cells 
and intestinal cells. The key function of SOX10 in the nervous 
system is its involvement in the development of Schwann 
cells and the eect on the dierentiation of oligodendrocy-
tes in the brain and spinal cord. Dierent patterns of SOX10 
protein expression in CNS tumors are reported. The results 
showed 100% expression of SOX10 in patients with diagnosed 
Schwannoma tumors, 98–100% in neurobromas, and much 
lower, 50–55 % in malignant peripheral nerve sheath tumor 
(MPNST) [24, 30, 37]. 
MPNST is a rare malignant tumor with an aggressive 
course constituting 2% sarcomas derived from soft tissues. 
This malignancy may occur in type I neurobromatosis after 
radiotherapy or sporadically [38]. In the diagnosis of MPNST, 
the S100 protein is routinely used as a stable and specic 
marker. Current studies showed that the expression of the 
SOX10 protein is comparable to the S100 protein in patients 
suering from neurobroma and schwannoma. Nonaka and et 
al. presented that SOX10 may be a more sensitive and specic 
marker of MPNST; 49% vs. 30% was positive to SOX10 and S100 
respectively. Moreover, it was also conrmed that granular 
cell tumors are associated with neoplastic nerve tumors that 
come together with the neural crest [24]. In addition, it was 
noted that the expression of SOX10 protein is almost always 
absent in tumors with which MPNST can be misdiagnosed 
[23]. It was conrmed that the evaluation of SOX10 strongly 
supports the dierential diagnostics of MPNST from synovial 
sarcoma [24, 37].
SOX10 in other malignancies
The presence of SOX10 was also demonstrated in salivary gland, 
breast and soft tissue tumors. Due to limited number of studies, 
the expression of SOX10 in epithelial tumors has still not been 
well established. SOX10 is rarely expressed in epithelial tumors 
with the exception of the salivary glands tumors, in which the 
presence of SOX10 has been conrmed by numerous studies 
[23, 24, 39, 40]. Nonaka et al. conrmed that SOX10 protein is 
expressed in myoepithelial cells [24]. The normal acinar and 
myoepithelial cells and tumors originating from those cells are 
SOX10 positive [23, 40]. Recently, a large group of patients with 
dierent salivary gland tumors was evaluated; the SOX10 expres-
sion depended on the histopathological type and presented as 
below: multiform adenoma – 79%, monomorphic adenomas 
– 100%, polymorphic adenocarcinoma of low malignancy – 
88%, adenoid cystic adenocarcinoma – 96% and adenocarci-
nomas – 96%. Moreover, there was no expression of the SOX10 
protein in the other subtypes of salivary gland tumors; which 
means that the determination of the SOX10 protein expression 
may be a good marker supporting the dierential diagnosis of 
some tumors subtypes [40, 41]. A few studies reported positive 
SOX10 expression in pheochromocytomas, PEComas and carci-
noid carcinomas [42]. In breast cancer there was also a positive 
expression of SOX10 [43]. Cimino-Mathews et al. conrmed its 
occurrence in patients with triple-negative or metaplastic breast 
cancer [39]. Malignant gastrointestinal neuroectodermal tumor, 
61
which was rst described as an ‘osteoclast-rich tumor of the 
gastrointestinal tract with features resembling clear cell sarcoma 
of soft parts’ in 2003, is also SOX10 positive even though it lacks 
melanocytic dierentiation [44]. Moreover, SOX genes probably 
play important roles in sarcoma cell pathogenesis, growth, and 
proliferation i.e.: SOX2 and SOX9 genes in osteosarcoma, chon-
drosarcoma and chordoma, SOX2, SOX6, and SOX17 genes in 
Ewing’s sarcoma, SOX2, SOX9, and SOX10 genes in synovial 
sarcoma, SOX2 gene in brosarcoma, and SOX21 gene in liposar-
coma [45]. In Figure 2, SOX10 expression in dierent tissues and 
tumors is presented. The frequency of positive SOX10 staining 
in soft tissue tumors is summarized in Table I. 
Anti-SOX10 antibodies in diagnostics
Immunohistochemical staining of SOX10 is possible due to 
the high availability of anti-SOX10 antibodies oered by the 
diagnostics market. Currently several monoclonal and po-
lyclonal antibodies are available, which are used for staining 
xed and para!n-embedded tissue material. The antibodies 
approved for routine diagnostics are produced by Cell Ma-
rque, Santa Cruz Biotechnology and Sigma Aldrich. Clones 
of monoclonal antibodies used in the diagnosis of SOX10 
protein are mainly A2, 1E6, EP268 and SP267. They are rabbit 
and mouse antibodies. At present, the polyclonal anti-SOX10 
antibody employed in routine diagnostics is the anti-SOX10 
polyclonal rabbit antibody oered by Cell Marque. In medi-
cal databases, dierent polyclonal antibodies, which have 
been used, might be found [46, 47]. The majority of published 
studies in immunohistochemistry staining utilized the Santa 
Cruz N-20 goat polyclonal antibody [23, 24]. Nevertheless, this 
antibody has been discontinued, and the new replacement 
is IgG1 monoclonal immunoglobulin with the A-2 clone. The 
manufacturer ensures that the new antibody is more specic, 
shows a stronger intensity and eliminates the variation in 
staining characteristic of each series of polyclonal antibodies. 
Recent literature has already revealed researches using the 
above-mentioned mouse monoclonal antibody IgG1 [48, 49].
Nevertheless, there are some controversies regarding the 
localization of SOX10 protein detection. Despite the fact that 
in most studies SOX10 staining shows a nuclear or nuclear 
reaction and weakly cytoplasmic staining, some reports show 
the perinuclear and cytoplasmic reactions [23, 24, 46]. The 
reason for these dierences is the type or clone of antibody 
which is used. In studies where SOX10 was nuclear or nuclear 
and weakly cytoplasmic, a goat N-20 polyclonal antibody 
from Santa Cruz Biotechnology and a polyclonal rabbit one 
from Cell Marque were used [24, 47]. In contrast, in the study, 
where the peri-nuclear and cytoplasmic reaction was shown, 
the Abcam anti-polyclonal rabbit antibody was applied. The 
authors interpreted the reaction as positive, which meant 
the presence of the SOX10 protein around nucleus and in 
cytoplasm. This protein probably appeared in these areas in 
the deactivated state [46].
Summary
1. Selective and specic expression of SOX10 in the mela-
nocytic lesions including melanoma, nervous and salivary 
glands tumors is reported.
2. The immunohistochemical staining of SOX10 may be 
helpful in the routine histopathological diagnostics of 
the above malignancies.
3. SOX10 may be the major or alternative marker for dieren-
tial diagnosis of melanoma from other lesions. The occur-
rence of a clear and extensive nuclear reaction facilitates 
the interpretation of the staining result.
4. SOX10 staining improves the diagnosis of desmoplastic 
melanoma and MPNST due to its higher sensitivity and 
specicity in comparison with other available markers.
5. In contrast to the S100 protein, the anti-SOX10 antibody 
does not demonstrate a positive staining result in dendritic 
cells, which facilitates its interpretation in lymph node 
evaluation.
6. A large scale research on the SOX10 protein expression 
in comparison to other melanocytic markers in sentinel 
lymph nodes is still needed, since there are no direct re-
commendations.
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Table I. The frequency of positive SOX10 staining in soft tissue tumors; the summary has been prepared on the basis of the following publications: 23, 24, 
30, 47, 50–52
Histopathological type Total number SOX10(+) cases % SOX10(+) cases
Schwannoma 190/197 97%
Neurobroma 134/137 98%
Granular cell tumor 143/153 93%
Malignant peripheral nerve sheath tumor 245/346 71%
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Figure 2. SOX10 immunostaining in dierent tumors. Schwannoma (100 x): A1 – HE, A2 – SOX10; MPNST (200 x): B1 – HE, B2 – SOX10. Myoepithelial 
carcinoma of breast, epithelioid neoplastic cells arranged in nests and trabelular pattern with abundant myxoid matrix: (40 x): C1 – PAS + Alcjan, C2 – 
SOX10. Invasive melanoma of skin (100 x), arrow: nerve, arrowhead: sweat ducts, star: melanoma: D1 – HE, D2 – SOX10
D1
C1
B1
A1
D2
C2
B2
A2
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